|
Jun 18
|
3 Reasons to Sell CRL and 1 Stock to Buy Instead
|
|
Jun 11
|
CRL Q1 Earnings Call: Regulatory Changes and Market Stabilization Shape Outlook
|
|
Jun 3
|
Drug Development Inputs & Services Q1 Earnings: UFP Technologies (NASDAQ:UFPT) Simply the Best
|
|
Jun 2
|
Charles River Stock May Gain From Extended CHDI Research Deal on HD
|
|
Jun 2
|
Charles River Laboratories to Present at William Blair and Jefferies Conferences
|
|
Jun 2
|
1 Value Stock with Impressive Fundamentals and 2 to Steer Clear Of
|
|
May 30
|
Charles River Laboratories International, Inc. (CRL): A Bull Case Theory
|
|
May 28
|
Charles River and CHDI Foundation Extend Multi-Decade Collaboration on Huntington’s Disease Research
|
|
May 24
|
Redburn Upgrades Charles River Laboratories (CRL) to Buy, Cuts PT
|
|
Apr 18
|
Charles River Laboratories International, Inc. (CRL): Among Mid-Cap Stocks Insiders Were Buying in Q1 2025
|
|
Apr 15
|
Charles River Laboratories Schedules First-Quarter 2025 Earnings Release and Conference Call
|
|
Apr 15
|
Strength Seen in Charles River (CRL): Can Its 6.9% Jump Turn into More Strength?
|
|
Feb 24
|
Deciphering Charles River (CRL) International Revenue Trends
|
|
Feb 24
|
UFP Technologies (UFPT) Reports Q4: Everything You Need To Know Ahead Of Earnings
|
|
Feb 21
|
Charles River Laboratories International Full Year 2024 Earnings: EPS Misses Expectations
|
|
Feb 20
|
Charles River Laboratories International Inc (CRL) Q4 2024 Earnings Call Highlights: Navigating ...
|
|
Feb 20
|
Q4 2024 Charles River Laboratories International Inc Earnings Call
|
|
Feb 19
|
Analyst Sees Charles River As Preclinical Leader But Maintains Neutral Stance
|
|
Feb 19
|
CRL Stock Up on Q4 Earnings and Revenue Beat, Margins Fall
|
|
Feb 19
|
Compared to Estimates, Charles River (CRL) Q4 Earnings: A Look at Key Metrics
|